Skip to main content

Table 3 BPI, BDI and HADS scores throughout the study (mean ± sd) (ES: effect sizes)

From: Trazodone plus pregabalin combination in the treatment of fibromyalgia: a two-phase, 24-week, open-label uncontrolled study

  baseline week 6 week 12 week 18 week 24 P
BPI mean severity 7.26 ± 1.6 6.69 ± 1.6 6.81 ± 1.8 6.33 ± 2-0 5.97 ± 2.3** 0.0028
ES   0.36 0.28 0.58 0.81  
BPI mean interference with daily activities 8.13 ± 1.6 6.90 ± 2.1** 6.60 ± 2.4*** 6.48 ± 2.4*** 5.93 ± 2.8*** <0.0001
ES   0.77 0.95 1.03 1.38  
BDI 28.0 ± 11.0 24.9 ± 13.1 21.5 ± 10.4*** 19.1 ± 9.9*** 19.3 ± 12.1*** <0.0001
ES   0.28 0.59 0.81 0.79  
BDI > 18 (N = 32) 31.2 ± 9.3 27.5 ± 12.7 23.2 ± 10.4*** 20.4 ± 10.1*** 20.8 ± 12.5*** <0.0001
ES   0.40 0.87 1.16 1.12  
HADS-A 13.9 ± 3.9 13.2 ± 4.5 12.0 ± 4.5* 11.9 ± 4.4** 11.5 ± 5.0** = 0.0003
ES   0.17 0.48 0.52 0.61  
HADS-A > 7 (N = 37) 14.4 ± 3.4 13.7 ± 4 12.5 ± 4.1* 12.4 ± 4.0* 12.0 ± 4.6** = 0.0008
ES   0.19 0.56 0.60 0.71  
HADS-D 12.2 ± 4.6 11.5 ± 4.7 10.6 ± 4.7 10.4 ± 5.0* 10.2 ± 4.9* = 0.0061
ES   0.16 0.36 0.41 0.45  
HADS-D > 7 (N = 34) 13.3 ± 3.7 12.4 ± 4.2 11.2 ± 4.5* 11.0 ± 4.7** 10.7 ± 4.7** = 0.0007
ES   0.25 0.58 0.63 0.71  
  1. *: p < 0.05, **: p < 0.01 and ***: p < 0.001 in relation to baseline (Tukey's post-test). Bold: large effect sizes.